Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Remain Bullish on CrowdStrike Holdings with Increased Price Targets

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Software-solutions-technology
0
SHARES
19
VIEWS
Share on FacebookShare on Twitter

Catharine Trebnick, an analyst at Rosenblatt, has reiterated her Buy rating on CrowdStrike Holdings (NASDAQ: CRWD) and raised the price target to $400, up from $375. This adjustment signifies her optimistic view on the company’s future performance.

In a similar vein, Truist Securities analyst has also increased the price target for CrowdStrike Holdings to $350, further bolstering confidence in the company’s potential for growth.

CrowdStrike Holdings (CRWD) Stock Price Drops 5.18% on March 6, Pre-Market Trading Shows Potential for Recovery

On March 6, 2024, CrowdStrike Holdings (CRWD) experienced a significant drop in its stock price, with shares decreasing by $16.25 or 5.18% since the market last closed. Despite the drop in price during regular trading hours, CRWD saw a substantial increase in pre-market trading, with the stock rising by $66.94. CrowdStrike Holdings is a cybersecurity technology company that provides cloud-based endpoint protection. Investors and analysts will be closely monitoring CRWD’s performance in the coming days to see if the stock can maintain its momentum and continue its upward trajectory. Overall, while the drop in CRWD’s stock price on March 6 may have been a temporary setback, the subsequent increase in pre-market trading suggests that investors remain optimistic about the company’s future prospects.

CRWD Stock Surges on Strong Financial Performance and Growth Prospects in Cybersecurity Industry

CrowdStrike Holdings, Inc. (CRWD) has been making waves in the cybersecurity industry with its innovative solutions and strong financial performance. On March 6, 2024, the company’s stock showed impressive growth, reflecting its solid financial results.

According to data from CNN Money, CrowdStrike reported total revenue of $2.24 billion for the past year, representing a 54.4% increase compared to the previous year. In the third quarter alone, the company generated $786.01 million in revenue, marking a 7.43% increase from the previous quarter.

In terms of net income, CrowdStrike reported a net loss of $183.25 million for the past year. However, the company showed significant improvement in its financial performance in the third quarter, with a net income of $26.66 million. This represents a 21.96% increase compared to the previous year and a remarkable 214.74% increase from the previous quarter.

Furthermore, CrowdStrike’s earnings per share (EPS) also showed impressive growth on March 6, 2024. The company reported an EPS of -$0.79 for the past year, which increased by 23.96% compared to the previous year. In the third quarter, CrowdStrike’s EPS stood at $0.11, marking a substantial 212.57% increase from the previous quarter.

Overall, CrowdStrike’s stock performance on March 6, 2024, reflects the company’s strong financial results and growth prospects in the cybersecurity industry. With its innovative solutions, expanding customer base, and solid financial performance, CrowdStrike is well-positioned for continued success in the market. Investors may view CrowdStrike as a promising investment opportunity based on its impressive revenue growth, improving profitability, and strong earnings growth.

Tags: CRWD
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Revolutionizing Fibromyalgia Treatment Tonix Pharmaceuticals and EVERSANA Partner to Launch Tonmya

Jefferies Analyst Upgrades Corbus Pharmaceuticals to Buy Raises Price Target

Analyst Raises Price Target for American Public Education to 15

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com